Sacubitril/Valsartan-induced Angioedema.
作者信息
Hiraoka Yuki, Nagayama Koji
机构信息
Department of Respiratory Medicine, Hamamatsu Medical Center, Japan.
Department of Endocrinology and Metabolism, Hamamatsu Medical Center, Japan.
出版信息
Intern Med. 2024;63(18):2583. doi: 10.2169/internalmedicine.3183-23. Epub 2024 Sep 15.
Abstract
摘要
相似文献
1
Sacubitril/Valsartan-induced Angioedema.沙库巴曲缬沙坦所致血管性水肿。
Intern Med. 2024;63(18):2583. doi: 10.2169/internalmedicine.3183-23. Epub 2024 Sep 15.
2
Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.血管性水肿聚焦：沙库巴曲缬沙坦安全性结果的深入研究
J Am Board Fam Med. 2017 Jul-Aug;30(4):556-557. doi: 10.3122/jabfm.2017.04.170111.
3
Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor.
Am J Ther. 2018 Jul/Aug;25(4):e508-e509. doi: 10.1097/MJT.0000000000000600.
4
Sacubitril/Valsartan-Associated Small Bowel Ileus.
Am J Ther. 2018 Nov/Dec;25(6):e705-e706. doi: 10.1097/MJT.0000000000000720.
5
Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.沙库巴曲缬沙坦五年——随机临床试验与真实世界药物警戒的安全性分析
Cardiovasc Drugs Ther. 2022 Oct;36(5):915-924. doi: 10.1007/s10557-021-07210-1. Epub 2021 Jun 14.
6
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
7
Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.沙库巴曲缬沙坦引起的血管性水肿：超过 14000 例患者的试验水平荟萃分析和迄今为止的真实世界证据。
Int J Cardiol. 2021 Jan 15;323:188-191. doi: 10.1016/j.ijcard.2020.08.067. Epub 2020 Aug 22.
8
The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data.沙库巴曲缬沙坦在≥75 岁老年人中的真实世界安全性：来自 FDA 数据的药物警戒研究。
Int J Cardiol. 2024 Feb 15;397:131613. doi: 10.1016/j.ijcard.2023.131613. Epub 2023 Nov 27.
9
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?沙库巴曲缬沙坦：对抗癌症治疗所致心脏毒性之战中的希望还是炒作？
Kardiol Pol. 2022;80(9):958-959. doi: 10.33963/KP.a2022.0166. Epub 2022 Jul 14.
10
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.沙库巴曲缬沙坦（诺欣妥®）所致低钠血症
J Pharm Pract. 2020 Oct;33(5):696-699. doi: 10.1177/0897190019828915. Epub 2019 Feb 18.
本文引用的文献
1
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.沙库巴曲缬沙坦与肾素-血管紧张素-醛固酮抑制剂的血管性水肿风险比较。
J Am Coll Cardiol. 2023 Jan 31;81(4):321-331. doi: 10.1016/j.jacc.2022.10.033.
2
Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials.血管紧张素受体脑啡肽酶抑制剂在心力衰竭管理中的疗效和安全性：系统评价和随机对照试验的荟萃分析。
Heart Fail Rev. 2023 Jul;28(4):905-923. doi: 10.1007/s10741-022-10273-3. Epub 2022 Oct 3.
Zotero 插件